GHRH signalling.
Stimulating the pituitary's GHRH receptor to release the body's own growth hormone.
Growth-hormone-releasing hormone is made in the arcuate nucleus of the hypothalamus and travels through the hypophyseal portal circulation to the anterior pituitary, where it binds a class B G-protein-coupled receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP, which triggers both the synthesis of growth hormone and its release in pulses. Downstream, growth hormone acts on the liver and peripheral tissues to raise insulin-like growth factor 1, and IGF-1 in turn feeds back to restrain further growth hormone output. Somatostatin, released from a separate hypothalamic population, provides the opposing brake. The appeal of targeting this receptor rather than administering growth hormone directly is that the feedback architecture stays intact. Because release remains pulsatile and IGF-1 can still shut the system down, the pituitary sets a ceiling on how much growth hormone appears. Direct growth hormone administration bypasses that ceiling entirely. This is the central argument for the whole class, and it is a genuine pharmacological difference rather than a marketing distinction. All compounds in this group are analogs of the biologically active fragment of GHRH, which is the first twenty-nine amino acids. Native GHRH is cleaved almost immediately by dipeptidyl peptidase-4 at the amino terminus, so every analog is essentially a different answer to that vulnerability. Some substitute amino acids near the cleavage site. Some add a chemical group at the amino terminus that the enzyme cannot process. Some attach a linker that lets the molecule bind covalently to circulating albumin, stretching duration from minutes to days and turning discrete pulses into a sustained elevation, which is a meaningfully different physiological signal from a short pulse. One member of this group is an approved medicine for a specific indication, which means the receptor mechanism has been demonstrated in humans and not merely in animals. That approval does not extend to the rest of the group. Most of the compounds here have never been approved for any use anywhere, are sold as research chemicals of unverified identity and purity, and have human data limited to short studies showing that growth hormone rises after administration. Demonstrating that a hormone level moves is not the same as demonstrating that anything clinically meaningful follows from it, and for most of this class that second step has not been taken.
Peptides acting through this pathway.
FAQ.
What does ghrh signalling do?
Growth-hormone-releasing hormone is made in the arcuate nucleus of the hypothalamus and travels through the hypophyseal portal circulation to the anterior pituitary, where it binds a class B G-protein-coupled receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP, which triggers both the synthesis of growth hormone and its release in pulses. Downstream, growth hormone acts on the liver and peripheral tissues to raise insulin-like growth factor 1, and IGF-1 in turn feeds back to restrain further growth hormone output. Somatostatin, released from a separate hypothalamic population, provides the opposing brake. The appeal of targeting this receptor rather than administering growth hormone directly is that the feedback architecture stays intact. Because release remains pulsatile and IGF-1 can still shut the system down, the pituitary sets a ceiling on how much growth hormone appears. Direct growth hormone administration bypasses that ceiling entirely. This is the central argument for the whole class, and it is a genuine pharmacological difference rather than a marketing distinction. All compounds in this group are analogs of the biologically active fragment of GHRH, which is the first twenty-nine amino acids. Native GHRH is cleaved almost immediately by dipeptidyl peptidase-4 at the amino terminus, so every analog is essentially a different answer to that vulnerability. Some substitute amino acids near the cleavage site. Some add a chemical group at the amino terminus that the enzyme cannot process. Some attach a linker that lets the molecule bind covalently to circulating albumin, stretching duration from minutes to days and turning discrete pulses into a sustained elevation, which is a meaningfully different physiological signal from a short pulse. One member of this group is an approved medicine for a specific indication, which means the receptor mechanism has been demonstrated in humans and not merely in animals. That approval does not extend to the rest of the group. Most of the compounds here have never been approved for any use anywhere, are sold as research chemicals of unverified identity and purity, and have human data limited to short studies showing that growth hormone rises after administration. Demonstrating that a hormone level moves is not the same as demonstrating that anything clinically meaningful follows from it, and for most of this class that second step has not been taken.
Which peptides act through ghrh signalling?
Sermorelin, CJC-1295, CJC-1295 DAC, Mod-GRF (1-29), Tesamorelin. They share this pathway but differ in evidence, approval, and safety.
Does this mechanism prove a peptide works?
No. Mechanistic plausibility is not proof of clinical benefit. A plausible pathway is a reason to study a compound, not evidence that it works in humans.